Skip to main content
AVTR logo

Avantor, Inc. (AVTR) Stock: Price, Forecast & Analyst Target

Avantor, Inc. (AVTR) — MoonshotScore 71/100 (Strong band), calculated Nov 18, 2026. Price $14.84 (-1.85%), as of the Nov 20, 2026 trading session; market cap $10.1B. Expected results Feb 10, 2027.

Educational signal · not a buy or sell recommendation · How to read this

Market value / cash and short-term investments: 21.75× (cash as of Sep 30, 2026) · expected results Feb 10, 2027

$14.84 −$0.28 (-1.85%) Market Cap $10.1B

Avantor, Inc. · AVTR · NYSE · Healthcare · Medical - Instruments & Supplies

Research dated 2026-09-13 (results through the quarter ended Jun 2026; the quarter ended Sep 2026 not covered): Avantor supplies laboratories and biopharmaceutical production sites with proprietary and externally sourced materials, consumables, equipment and on-site services; it is more exposed to routine scientific workflows than its instruments-and-supplies classification suggests. The question is whether that recurring demand can restore durable growth and generate enough cash to reduce a debt load that remains far larger than available liquidity.

Price as of Nov 20, 2026

Key Statistics

71 of 100

MoonshotScore v2 · Avantor (AVTR)

Strong
Business Quality Solid (72)
Financial Safety Strained (32)
Valuation Fair (67)
Growth Durability Flat (53)
Momentum Surging (95)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

High quality, but a strained balance sheet; the market is already moving on it. Business Quality: Solid; Financial Safety: Strained; Valuation: Fair; Growth Durability: Flat; Momentum: Surging.

  • EPS beat 5 of the last 8 reports
  • Altman Z 2.15 · Piotroski F 7
  • ROE 6.0% · ROA 2.9% · current ratio 1.89 · earnings yield 3.3% · free-cash-flow yield 4.2%

Holding back: balance-sheet strain

Helping: business quality, positive momentum

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for AVTR (58 recorded, newest six shown)
RecordedScoreBand
63Fair
63Fair
63Fair
71Strong
71Strong
71Strong

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$14.84
Change on the day-1.85%
52-week range$7.26–$17.45
Market capitalisation$10.1B—
Price / earnings (trailing)30.29
Shares traded on the day12.25M
Beta (volatility vs the S&P 500)0.95

Why Avantor scores 71

Dr. Mira Sol, the Stock Expert AI TV data character
Momentum carries the score; Financial Safety is what holds it back.
Dr. Mira Sol · Data scientist, Stock Expert AI TV (fictional AI character)
71Strong
  • Business Quality72
  • Financial Safety32
  • Valuation67
  • Growth Durability53
  • Momentum95

Share price, last 12 months +36.8%

$11.50 $15.73

What the price assumes

9.8% a year of free-cash-flow growth for ten years is what a $10.66B market value ( snapshot) asks for.

  • Price implies, next ten years9.8%
  • Free cash flow, last 5 years-10.6%
  • Revenue, last 5 years0.5%
  • Analysts' revenue path, 2026–20303.3%

The price already assumes faster growth than the last 5 years delivered. Anything short of an acceleration leaves room to disappoint. It also runs ahead of the analysts' revenue path.

Reverse discounted cash flow: 10% discount rate, 3% growth after year ten, starting from trailing twelve months free cash flow of $439.20M. Inputs: FMP statements, estimates and quote.

How the stock reacts to earnings

EPS beat in 9 of the last 12 reports (2024–2026); the stock still fell the next session after 5 of those beats. Average first-session move: 11.7% either way.

  1. +8.6%Feb ’24
  2. -4.3%Apr ’24
  3. +15.0%Jul ’24
  4. -2.7%Oct ’24
  5. -12.4%Feb ’25
  6. -19.4%Apr ’25
  7. -15.9%Aug ’25
  8. -26.7%Oct ’25
  9. -18.1%Feb ’26
  10. +3.1%Apr ’26
  11. +11.6%Jul ’26
  12. -2.6%Oct ’26
Next-session move EPS beat (9) EPS in line (1) EPS miss (2)
Every report, with revenue and five-session moves
Moves run from the close before the report to the first and fifth closes after it.
ReportEPSRevenueNext session5 sessions
BeatBeat-2.6%-8.6%
BeatBeat+11.6%+7.6%
BeatBeat+3.1%+7.3%
BeatBeat-18.1%-17.5%
MissMiss-26.7%-23.2%
MissBeat-15.9%-14.4%
In lineMiss-19.4%-17.0%
BeatBeat-12.4%-17.6%
BeatIn line-2.7%-4.1%
BeatIn line+15.0%+12.2%
BeatIn line-4.3%-1.7%
BeatBeat+8.6%+11.1%

Misses cost real money here: the average first-session move after a miss was -21.3%.

What management is saying differently

Management's own words on the Q3 FY2026 call () against Q2 FY2026 (). Analysts' questions are left out.

  • Getting louder: “ebitda margin” (2 → 6 mentions), “margin expansion” (2 → 4 mentions).
  • Gone quiet: “large global”, “vwr com”, “e-commerce platform”, “forward-looking statements” — regular themes last call, absent this time.

The tone held steady from one call to the next; what changed is the subject matter, not the confidence.

Our track record on this stock

Since the score went from 53 to 71 while the share price moved +4.1% through .

MoonshotScore (0–100, band floors 45 · 65 · 80) Share price, scaled to its own range
Band changes, newest first. “Right” means the price moved the way the change pointed over the next three months.
DateBand3 months6 monthsCall
Fair → Strong———

The one band change we have recorded has not been graded yet; we grade each band change three months after it happens.

The crowd against our signals

  • Analysts: 31% of 26 rate it a buy; the average target sits -2.0% from the price of $14.84.
  • Last 90 days: 8 rating actions, every one a reaffirmation.
  • Our signals: Strong band; strongest pillar Momentum (95), weakest Financial Safety (32).

Our signals are more constructive than the crowd, led by Momentum.

Price & events

Weekly closing price with reported quarters marked Weekly closing price from Oct 17, 2025 to Nov 20, 2026: low $7.41, high $17, latest $15. 4 reported quarters marked, 4 above and 0 below the recorded estimate. 1 other dated event marked. $17 $7.41 high $17 Feb 11, 2026 · Earnings results · reported above the recorded estimate · close $9.201Apr 29, 2026 · Earnings results · reported above the recorded estimate · close $7.962Jul 29, 2026 · Earnings results · reported above the recorded estimate · close $143Oct 28, 2026 · Earnings call · management outlook · no recorded estimate to compare · close $164Oct 28, 2026 · Earnings results · reported above the recorded estimate · close $165 Oct 17, 2025 Nov 20, 2026 · $15 $15Oct 17, 2025$12Oct 31, 2025$11Nov 14, 2025$12Nov 28, 2025$11Dec 12, 2025$11Dec 26, 2025$12Jan 9, 2026$12Jan 23, 2026$11Feb 6, 2026$9.03Feb 20, 2026$8.17Mar 6, 2026$7.51Mar 20, 2026$7.90Apr 2, 2026$8.52Apr 17, 2026$7.96May 1, 2026$7.62May 15, 2026$9.12May 29, 2026$9.39Jun 12, 2026$10Jun 26, 2026$10Jul 10, 2026$11Jul 24, 2026$14Aug 7, 2026$14Aug 21, 2026$15Sep 4, 2026$16Sep 18, 2026$15Oct 2, 2026$16Oct 16, 2026$16Oct 30, 2026$16Nov 13, 2026

Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file or a dated event that is not a results report. Numbers key to the dated list. Point at or tab to any week for its close.

Events behind the price

  • · Earnings results · above the recorded estimate
  • · Earnings results · above the recorded estimate
  • · Earnings results · above the recorded estimate
  • · Earnings call · management outlook
  • · Earnings results · above the recorded estimate

Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.

Upcoming events

As of

  1. Next results dueProvider estimate

Management outlook

  • As a result, we now expect foreign exchange to contribute approximately 75 basis points to full year reported revenue growth.

    Steven W. Eck · Statement from

  • We anticipate that our adjusted EBITDA margin will expand modestly from Q3 to Q4.

    Steven W. Eck · Statement from

How to read these dates

A statement's date is the earnings call where it was made, not a deadline. Management expectations and estimated dates can change.

Read management statements

Other perspectives

Council score for Avantor (AVTR): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

5-Factor Breakdown

Business Quality Moderate
Financial Safety Weak
Valuation Moderate
Growth Durability Neutral
Momentum Strong

Legends Council

6 lenses, 6 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Favorable read
Simons-style lens (simulated) Jim Simons Neutral read
Englander-style lens (simulated) Izzy Englander Neutral read
Klarman-style lens (simulated) Seth Klarman Favorable read
Moon AI lens (model) Neutral read

Read on: Nov 20, 2026

Munger's Mindset

Balance Sheet & Valuation

Financial Health Neutral
Margin of Safety Fairly Valued
Profit Margin Neutral
Revenue Growth Negative
Debt/Equity Weak
ROE Neutral
Gross Margin Neutral

Read on: Nov 21, 2026

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

The Munger lens reads the current price as fairly valued against its own estimate of value.

Readings on this page are from Nov 21, 2026, except a card that shows its own read date.

1 · What is it?

What is Avantor (AVTR), and what does it report?

Short answer · as of

Avantor sells chemicals, reagents, laboratory supplies, process materials, fluid-handling products and specialized services to biopharmaceutical, healthcare, education, government and advanced-technology customers.

Instruments are part of the portfolio, but the business is principally a materials-and-consumables platform serving research, clinical and production workflows.

Reported revenue is divided between Avantor’s proprietary materials and consumables and products sourced from outside manufacturers. Proprietary offerings contribute slightly more revenue, so reported sales combine manufacturing economics with distribution and service activity rather than measuring a pure equipment business.

2 · Latest results

What do the latest results show for Avantor (AVTR)?

The latest reported period brought a sequential revenue rebound and modest growth against the comparable period, while gross profit and operating profit remained below their comparable levels. Net income stayed positive but weakened, leaving the recovery in sales stronger than the recovery in profitability. Revenue and earnings also exceeded consensus in the recent reporting run after a more uneven stretch of surprises.

Management updated its organic revenue outlook, expects currency translation to support reported revenue and retained its free-cash-flow outlook. Those statements describe management’s expectations; the reported record still shows a multi-period annual revenue contraction and an annual loss shaped by a large earlier-period deficit.

Where is operating spending going?

Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.

Latest quarter · revenue
$1.70B Sep 30, 2026
Latest quarter · SG&A
$395.30M Sep 30, 2026
Latest quarter · FMP standardized operating result
$139.50M Sep 30, 2026
Period endRevenueR&DSG&AFMP standardized operating result
Sep 30, 2026$1.70BNot available$395.30M$139.50M
Jun 30, 2026$1.69BNot available$415.20M$121.80M
Mar 31, 2026$1.58BNot available$0.00$115.00M
Dec 31, 2025$1.66BNot available$392.40M$126.40M
How to read these figures

Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.

Did results meet expectations?

Reported earnings and revenue alongside the estimates recorded by the provider.

Latest report · revenue
$1.70B Oct 28, 2026
Latest report · revenue estimate
$1.64B Oct 28, 2026
Latest report · revenue vs estimate
Above estimate Oct 28, 2026
Latest report · EPS vs estimate
Above estimate Oct 28, 2026
Report dateRevenue · reportedRevenue · estimateEPS · reportedEPS · estimate
Oct 28, 2026$1.70B$1.64B$0.2200$0.2090
Jul 29, 2026$1.69B$1.61B$0.2100$0.1915
Apr 29, 2026$1.58B$1.54B$0.1700$0.1570
Feb 11, 2026$1.66B$1.64B$0.2200$0.2100
How to read these figures

Dates are when results were reported, not quarter ends. Amounts are in US dollars; EPS is per share. The source does not say whether EPS is basic, diluted or adjusted, so it can differ from the EPS in the income statement.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Sep 2026$1.70B$203M$0.30 (diluted)
Jun 2026$1.69B$38M$0.06 (diluted)
Mar 2026$1.58B$43M$0.06 (diluted)
Dec 2025$1.66B$52M$0.08 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Avantor (AVTR)?

Short answer · as of

Cash and short-term investments were $464.30M at the Sep 30, 2026 balance-sheet date. Operating cash flow was $195.10M for the quarter ended Sep 30, 2026, meaning operations generated cash. These figures do not establish a cash runway.

Operating cash flow has remained positive throughout the displayed history and strengthened sharply from the preceding period, while capital spending has consumed a comparatively modest share of that inflow. This gives Avantor meaningful cash-generation capacity even though accounting profitability has been disrupted.

Debt towers over cash and short-term investments, leaving the company in a substantial net-debt position. Liquidity ratios indicate coverage of near-term obligations, but the trailing margin set remains negative; weaker demand or another profit shock could therefore slow deleveraging even if operations continue producing cash.

How much cash does the business generate or use?

Quarterly operating cash flow shows cash generated or used by operations.

Latest quarter · operating cash flow
$195.10M Sep 30, 2026
Previous quarter · operating cash flow
$178.20M Jun 30, 2026
Period endOperating cash flowCapital expenditure (reported)
Sep 30, 2026$195.10M−$38.90M
Jun 30, 2026$178.20M−$37.60M
Mar 31, 2026$58.70M−$33.50M
Dec 31, 2025$152.70M−$35.50M
How to read these figures

Amounts are in US dollars. Negative operating cash flow means the business used cash. Capital spending is shown as reported; we do not combine it into a free-cash-flow or runway estimate. The bars share one scale.

4 · What to check next?

What should you watch next at Avantor (AVTR)?

Short answer · as of

The next earnings report is expected on Feb 10, 2027. The number it tests is the $0.82 EPS analysts carry for it.

Watch whether proprietary and externally sourced consumables sustain the latest revenue improvement, and whether gross profit and operating profit begin to follow. Another sales beat without comparable profit recovery would point to a weaker earnings mix or cost conversion, although the available figures do not isolate either cause.

Cash conversion is the balance-sheet test: operating cash flow must remain comfortably above capital spending if management’s outlook is to translate into greater debt capacity. Consensus expects the upcoming report to surrender some of the latest revenue level, while the longer forecast path assumes gradual improvement in revenue and earnings.

What management is planning

Management expectations, not completed milestones or guarantees. Selected verbatim excerpts; dates follow the transcript provider.

  1. In 2026, we now expect an adjusted effective tax rate between 22% and 22.5% and a weighted average diluted share count of 679 million shares.

    Steven W. Eck ·

  2. We now expect free cash flow between $520 million and $550 million in 2026, reflecting our year to date financial performance, and the strength and consistency of Avantor's cash generation profile.

    Steven W. Eck ·

2 more statements are quoted under Upcoming events

5 · Peer comparison

How does Avantor compare with its peers?

Short answer

Avantor's score ranks tied for 8th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Avantor differs from a pure laboratory-instrument manufacturer because much of its revenue comes from materials consumed during research, testing and production rather than from occasional equipment purchases. It also differs from a pure distributor because proprietary chemicals, excipients, silicone materials and bioprocess products contribute slightly more revenue than externally sourced consumables.

That hybrid structure makes customer activity inside laboratories and production facilities more important than equipment replacement alone. Services such as on-site support, sourcing, maintenance and biopharmaceutical scale-up further embed Avantor in customer workflows, but the current financial record shows that this breadth has not prevented revenue contraction.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
West Pharmaceutical Services, Inc. (WST) Same industry, near in market value$396.69 Nov 19, 2026$27.6B92 5-pillar Nov 18, 2026
Haemonetics Corporation (HAE) Same industry, near in market value$120.16 Nov 20, 2026$5.47B83 5-pillar Nov 18, 2026
Merit Medical Systems, Inc. (MMSI) Same industry, near in market value$84.34 Nov 20, 2026$5.05B81 5-pillar Nov 18, 2026
AptarGroup, Inc. (ATR) Named competitor$140.08 Nov 20, 2026$8.88B77 5-pillar Nov 18, 2026
Henry Schein, Inc. (HSIC) Named competitor$83.52 Nov 20, 2026$9.23B73 5-pillar Nov 18, 2026
ICU Medical, Inc. (ICUI) Same industry, near in market value$172.52 Nov 20, 2026$4.31B73 5-pillar Nov 18, 2026
Stevanato Group S.p.A. (STVN) Same industry, near in market value$15.65 Nov 20, 2026$4.27B73 5-pillar Nov 18, 2026
Avantor (AVTR) — this page$14.84$10.1B71
Repligen Corporation (RGEN) Same industry, near in market value$163.81 Nov 20, 2026$10.5B71 5-pillar Nov 18, 2026
Molina Healthcare, Inc. (MOH) Named competitor$198.39 Nov 20, 2026$10.4B68 5-pillar Nov 18, 2026
Teleflex Incorporated (TFX) Same industry, near in market value$161.58 Nov 20, 2026$6.41B61 5-pillar Nov 18, 2026
Baxter International Inc. (BAX) Named competitor$25.39 Nov 20, 2026$13.1B57 5-pillar Nov 18, 2026
The Cooper Companies, Inc. (COO) Same industry, near in market value$58.88 Nov 20, 2026$11.2B40 5-pillar Nov 18, 2026

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

Screen more Healthcare stocks

The records behind this page

Analyst targets & estimates

What analysts have on file

Price target, low to high
$7.00 – $18.00
Consensus target
$14.55
Median target
$16.00
Revenue estimate
$6.67B
EPS estimate
$0.82

Consensus record · Captured .

Measured against a quoted price of $14.84 (as of Nov 20, 2026).

Insider activity

Form 4 records via FMP · Of the newest 500 records, those within the last 180 days, newest dated Nov 10, 2026

Transactions
10
Identified insiders
7
Purchases
0
Sales
0
Other transactions
10

Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

Who holds the shares?

Institutional ownership reported through 13F filings.

Institutional ownership
99.9% Period end Sep 30, 2026
Reporting holders
513 Period end Sep 30, 2026
Previous quarter · holders
471 Prior to period end Sep 30, 2026
Holders in provider snapshotShares
Dodge & Cox119,275,869
Blackrock, INC.70,982,979
Vanguard Portfolio Management LLC31,311,591
Vanguard Capital Management LLC30,368,763
Dimensional Fund Advisors LP24,758,642

Tracked investors

Which of the 16 named investors we follow held AVTR in their latest 13F filing, and what they did against the filing before it.

InvestorManager13F quarterPortfolio weightValueLast quarter
Bridgewater AssociatesFounded by Ray DalioQ3 20260.09%$20.87MAdded +360.4% shares

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Holder snapshot as of Sep 30, 2026. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about Avantor (AVTR)?

Read these with our analysis →

Avantor Healthcare Stock: Key Questions Answered

The last 2 questions are answered from this page's own dated data, not from the research.

Does Avantor mainly sell laboratory instruments?

Materials, consumables and specialized services form the core of Avantor’s business, while instruments are only part of a broader laboratory and production portfolio. Its segment revenue is entirely classified between proprietary and externally sourced materials and consumables.

What makes Avantor’s proprietary materials important?

Proprietary materials include specialized chemicals, excipients, silicone formulations and bioprocess products used within customer workflows. They contribute slightly more revenue than externally sourced consumables, giving Avantor meaningful product exposure alongside distribution.

Why does biopharmaceutical activity matter to Avantor?

Avantor supplies biopharmaceutical customers with process materials, chromatography products, fluid-handling equipment, clinical kits and development support. Changes in research and production activity can therefore reach product sales and service demand through the same customer workflow.

What would validate Avantor’s updated organic revenue outlook?

Sustained demand across proprietary and externally sourced consumables, accompanied by better gross and operating profit, would make the revenue improvement more convincing. Cash flow remaining well above capital spending would also support management’s retained cash-generation outlook.

What is the AVTR stock price today?

The last price recorded for Avantor, Inc. (AVTR), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is the AVTR price target?

The analyst consensus price target for Avantor, Inc. (AVTR), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.

Research written by Codex (gpt-5.6-sol) on 2026-09-13. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 77 figures on this page — 2 from SEC filings and earnings calls, 65 from Financial Modeling Prep (FMP), 6 with no recorded source, 3 computed by us, formula shown in the register and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections

Sources (as of 2026-09-13), by section of the research

  • Summary at the top of the page: Business description; Sector / industry (provider taxonomy); Revenue by segment; Annual revenue and net result (USD millions); Operating cash flow by quarter (USD millions); Cash, investments and debt
  • 1. What is Avantor (AVTR), and what does it report?: Business description; Sector / industry (provider taxonomy); Revenue by segment
  • 2. What do the latest results show for Avantor (AVTR)?: Quarterly income statement (USD thousands); Annual revenue and net result (USD millions); Reported versus estimated, last 8 quarters; Management outlook — dated call excerpts
  • 3. What are the financial strengths and risks for Avantor (AVTR)?: Operating cash flow by quarter (USD millions); Cash, investments and debt; Cash and investment components; Cash and short-term investments over time (USD millions); Cash against market value; Trailing twelve-month ratio set
  • 4. What should you watch next at Avantor (AVTR)?: Revenue by segment; Quarterly income statement (USD thousands); Operating cash flow by quarter (USD millions); Cash, investments and debt; Reported versus estimated, last 8 quarters; Next earnings report; Analyst revenue and earnings estimates (average); Management outlook — dated call excerpts
  • 5. How does Avantor compare with its peers?: Business description; Sector / industry (provider taxonomy); Revenue by segment; Annual revenue and net result (USD millions)
  • FAQ: Does Avantor mainly sell laboratory instruments?: Business description; Revenue by segment
  • FAQ: What makes Avantor’s proprietary materials important?: Business description; Revenue by segment
  • FAQ: Why does biopharmaceutical activity matter to Avantor?: Business description
  • FAQ: What would validate Avantor’s updated organic revenue outlook?: Revenue by segment; Quarterly income statement (USD thousands); Operating cash flow by quarter (USD millions); Management outlook — dated call excerpts
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.